GeoVax Labs, Inc.
GOVX evidence brief
What we can confirm
- BioSniper Score:
- 6.5 / 10
- Market Cap:
- $4.2M
- Lead Asset:
- gedeptin (Phase 2)
What it means
What to watch
Prepared research question
What matters most for GOVX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · GOVX
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and solid tumor cancers, with a primary near-term focus on advancing its GEO-MVA poxvirus vaccine candidate through an expedited European regulatory pathway.
Key risk: Cash runway limited
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$4.2M
Cash Runway
—
Lead Asset
gedeptin (Phase 2)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 1 clinical trial for GeoVax Labs, Inc..
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and solid tumor cancers, with a primary near-term focus on advancing its GEO-MVA poxvirus vaccine candidate through an expedited European regulatory pathway.
- GeoVax is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms [sec · filed 2026-09-17].
- The primary near-term strategic development priority is GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses, being advanced on an expedited regulatory pathway in Europe [sec · filed 2026-09-17].
- The lead oncology program is Gedeptin®, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers [sec_mda · as of 2026-04-15].
- As of 2026-06-30, the company reported cash & equivalents of $3.1M, total revenue of $0.0M, net income of -$4.4M, and shareholders' equity of $1.8M [sec].
- A Phase 2 clinical trial evaluating Gedeptin® in combination with an immune checkpoint inhibitor as first-line treatment for squamous cell head and neck cancer is planned for the first half of 2027 [sec_mda · as of 2026-04-15].
What works
- GeoVax has a clear near-term regulatory pathway for GEO-MVA in Europe, targeting a significant global supply constraint for orthopoxvirus vaccines [sec · filed 2026-09-17].
- The company has multiple clinical-stage programs, including GEO-CM04S1 (COVID-19 vaccine) showing superior immune responses versus an mRNA vaccine in interim DSMB review for CLL patients [sec_mda · as of 2026-04-15].
- GeoVax collaborates with academic, governmental, and industry partners to validate technologies and support development efforts [sec · filed 2026-04-16].
What to weigh
- GeoVax reported zero total revenue and a net loss of -$4.4M as of 2026-06-30, indicating no product sales and ongoing cash burn [sec].
- Cash and equivalents stood at $3.1M as of 2026-06-30, which may limit operational runway given the company's clinical-stage expenditures [sec].
- The company's lead oncology program, Gedeptin®, is still in early stages (Phase 1/2 completed) with a Phase 2 trial not planned until first half of 2027, implying a long path to potential commercialization [sec_mda · as of 2026-04-15].
From the filings
Quoted directly from source documents.
GeoVax is a clinical-stage biotechnology company developing vaccines and immunotherapies.
“GeoVax Labs, Inc. ("GeoVax", "us", "we" or the "Company") is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms.”
SEC filings · September 17, 2026
GEO-MVA is the primary near-term strategic priority, advancing on an expedited regulatory pathway in Europe.
“GeoVax's primary near-term strategic development priority is the advancement of GEO-MVA, a Modified Vaccinia Ankara ("MVA") vaccine candidate for mpox, smallpox, and other poxviruses. GEO-MVA is being advanced on an expedited regulatory pathway in Europe”
SEC filings · September 17, 2026
Gedeptin® completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers.
“The Company's lead clinical program in oncology is Gedeptin®, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers.”
SEC filings · April 15, 2026
Risks & what to watch (4)›
Key risks
- Cash runway limited — Cash & equivalents of $3.1M as of 2026-06-30 may be insufficient to fund ongoing clinical programs without additional financing [sec].
- No revenue generation — Total revenue of $0.0M as of 2026-06-30 indicates no product sales, relying entirely on external funding [sec].
- Clinical trial delays — Phase 2 trial for Gedeptin® not planned until first half of 2027, with no guarantee of success [sec_mda · as of 2026-04-15].
- Regulatory uncertainty — GEO-MVA's expedited pathway in Europe may face regulatory hurdles or competitive pressures [sec · filed 2026-09-17].
What to watch
- Initiation of pivotal Phase 3 clinical trial for GEO-MVA in the second half of 2026 [sec · filed 2026-05-26].
- Data readouts from GEO-CM04S1 Phase 2 trials, anticipated in the first half of 2026 [sec · filed 2026-04-16].
- Initiation of Phase 2 clinical trial for Gedeptin® in combination with an ICI in the first half of 2027 [sec_mda · as of 2026-04-15].
- Changes in cash position and financing activities, as net cash provided by financing activities was $7.3M in the period ending June 30, 2026 [sec · filed 2026-09-17].
Sources: SEC filings · SEC MD&A · Generated October 11, 2026 · How we verify sources →
Run GeoVax Labs, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available GeoVax Labs, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 1.64
Lead: Phase 3
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
16
Total value held
$446K
| Holder | Shares | Value |
|---|---|---|
| armistice capital, llc | 269,253 | $372K |
| geode capital management, llc | 36,076 | $50K |
| vanguard fiduciary trust co | 5,068 | $7K |
| ubs group ag | 4,248 | $6K |
| tower research capital llc (trc) | 3,527 | $5K |
| vanguard capital management llc | 3,217 | $4K |
| blackrock, inc. | 1,093 | $2K |
| sbi securities co., ltd. | 384 | $530 |
| wells fargo & company/mn | 31 | $43 |
| virtu financial llc | 10,478 | $14 |
Showing top 10 of 16 institutional holders of GeoVax Labs, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 9.6%
- Days to cover
- 3.8
- Shares short
- 277,558
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
GOVX short interestGovernance
Frequently asked questions
What is the AI investment thesis for GeoVax Labs, Inc.?
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and solid tumor cancers, with a primary near-term focus on advancing its GEO-MVA poxvirus vaccine candidate through an expedited European regulatory pathway.
What is GeoVax Labs, Inc.'s lead drug candidate?
GeoVax Labs, Inc.'s most advanced tracked candidate is gedeptin (Phase 2) for advanced head and neck squamous cell carcinoma (HNSCC).
Who is the CEO of GeoVax Labs, Inc.?
Mr. David Alan Dodd is the chief executive officer of GeoVax Labs, Inc. (GOVX).
Where is GeoVax Labs, Inc. headquartered?
GeoVax Labs, Inc. (GOVX) is headquartered in Smyrna, GA, United States.
What therapeutic areas does GeoVax Labs, Inc. focus on?
GeoVax Labs, Inc. develops therapies across Oncology, Infectious Disease.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.